Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ONCSQ.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
January 31, 2023 4.499M
October 31, 2022 -0.3433M
July 31, 2022 -0.2403M
April 30, 2022 -0.3723M
January 31, 2022 -0.1814M
October 31, 2021 -0.3676M
July 31, 2021 0.0106M
April 30, 2021 7.369M
January 31, 2021 47.45M
October 31, 2020 13.38M
July 31, 2020 -0.367M
April 30, 2020 29.05M
January 31, 2020 -0.2197M
October 31, 2019 -0.0634M
July 31, 2019 10.00M
April 30, 2019 2.221M
January 31, 2019 6.686M
October 31, 2018 8.288M
July 31, 2018 -0.0852M
April 30, 2018 21.31M
January 31, 2018 9.354M
October 31, 2017 8.303M
July 31, 2017 -0.011M
April 30, 2017 0.0326M
January 31, 2017 0.0035M
Date Value
October 31, 2016 0.0389M
July 31, 2016 9.190M
April 30, 2016 0.00
January 31, 2016 6.886M
October 31, 2015 0.00
July 31, 2015 12.49M
April 30, 2015 0.00
January 31, 2015 0.777M
October 31, 2014 0.00
July 31, 2014 16.67M
April 30, 2014 8.339M
January 31, 2014 5.075M
October 31, 2013 12.29M
July 31, 2013 -0.9606M
April 30, 2013 0.00
January 31, 2013 6.831M
October 31, 2012 -0.394M
July 31, 2012 0.00
April 30, 2012 7.058M
January 31, 2012 0.00
October 31, 2011 -0.10M
July 31, 2011 3.00M
April 30, 2011 1.058M
January 31, 2011 0.015M
October 31, 2010 0.0045M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 10.49M
Alnylam Pharmaceuticals, Inc. 36.24M
Anika Therapeutics, Inc. -0.701M
Savara, Inc. 0.189M
Vericel Corp. 2.692M